Prognostic value of the mutation types and dynamics of FLT3-ITD in acute myeloid leukemia

Eur J Haematol. 2023 Oct;111(4):562-572. doi: 10.1111/ejh.14044. Epub 2023 Jul 12.

Abstract

Objective: The prognostic value of the mutation types and dynamics of FLT3-ITD in acute myeloid leukemia (AML) and other known factors were studied.

Methods: Initial and follow-up samples from 45 AML patients with FLT3-ITD mutations were analyzed by fragment length analysis, Sanger sequencing, and next-generation sequencing.

Results: Some patients (13%) had multiple FLT3-ITD mutations, and many of them had acute promyelocytic leukemia (APL). FLT3-ITD mutations were classified according to mutation types, including duplication-only FLT3-ITD (52%) and FLT3-ITD with duplications and insertions (dup + ins) (48%). The dup + ins FLT3-ITD variant was independently associated with poor prognosis among non-APL patients (odds ratio, 2.92) in addition to FLT3-ITD with ≥50% variant allele frequency (VAF). The VAFs of FLT3-ITD were low (median 2.2%) when detected during morphologic complete remission (CR) after conventional chemotherapy; however, in two patients treated with gilteritinib after relapse, the VAFs of FLT3-ITD were much higher (>95% and 8.1%) in the morphologic CR state.

Conclusions: The type of FLT3-ITD mutation is important in prognosis, and the dup + ins type of FLT3-ITD can be an indicator of poor prognosis. In addition, the FLT3-ITD mutation status may unexpectedly not match the morphologic examination results after gilteritinib treatment.

Keywords: FLT3-ITD mutations; fragment length analysis; next generation sequencing.

MeSH terms

  • Humans
  • Leukemia, Myeloid, Acute* / diagnosis
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / genetics
  • Leukemia, Promyelocytic, Acute* / diagnosis
  • Mutation
  • Prognosis
  • fms-Like Tyrosine Kinase 3 / genetics

Substances

  • gilteritinib
  • fms-Like Tyrosine Kinase 3
  • FLT3 protein, human